Cabozantinib is a multitarget RTK inhibitor that inhibits several RTKs, including MET, RET, VEGFR-1-3, KIT, FLT-3, TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL, and it has been clinically approved for the treatment of medullary thyroid cancer (MTC) (33), renal cell cancer (RCC) (34), and hepatocellular carcinoma (HCC) (35). Here, NTRK2 is linked to renal cell adenocarcinoma.